Document:

Voting Agreement

 Exhibit 4.11 
 VOTING AGREEMENT 
 THIS VOTING AGREEMENT is made and
entered into as of this 3rd day of August, 2011, by and
among Exa Corporation, a Delaware corporation (the “Company”), Fidelity Ventures Limited (“FVL”), InfoTech Fund I LLC (“InfoTech”), FMR LLC (“FMR” and together with FVL and
InfoTech, the “Fidelity Entities”) and other Stockholders set forth on Schedule A1 hereto (the “Stockholders”). 
 RECITALS 
 WHEREAS, Mr. Paul Mucci (“Mr. Mucci”) is
currently serving on the board of directors of the Company (the “Board”); 
 WHEREAS, the
Company desires to undertake an initial public offering (“IPO”) pursuant to a registration statement on Form S-1 (the “Registration Statement”), in anticipation of which Mr. Mucci intends to resign from the
Board2; and 

WHEREAS, if the IPO is not consummated by the IPO Termination Date (as defined below), the Parties hereto desire to provide that FVL
shall have the right to fill the vacancy on the Board created by Mr. Mucci’s resignation. 
 WHEREAS, the Fidelity
Entities and the Company are entering into that certain side letter pursuant to which the Company has agreed to register certain shares of the Company’s common stock $.001 par value per share in the Registration Statement. 

NOW, THEREFORE, in consideration of the foregoing, the parties agree as follows: 

1. Board of Directors. 
 1.1. Board Appointment. In the event of (i) the withdrawal of the Registration Statement or abandonment of the IPO by the Company, as evidenced by the failure of the Company to file any
responsive amendment to the Registration Statement for a period of 60 days following the receipt of the most recent comment letter from the staff of the Securities and Exchange Commission with respect thereto, or (ii) the failure of the Company
to enter into a definitive underwriting agreement for the IPO by March 31, 2012 (an “IPO Termination”), the Company shall cause a special meeting of stockholders to be called no later than ten (10) business days thereafter
for the purpose of electing a director to the Board as designated in writing by FVL. Each Stockholder agrees to vote, or cause to be voted, at any such special meeting or by written consent in lieu thereof all shares of common stock and preferred
stock of the Company owned by such Stockholder or over which such Stockholder has voting control (collectively, the “Shares”), in whatever manner as shall be necessary to ensure that following an IPO Termination, one person
designated by FVL (the “FVL Designee”) who, if other than Mr. 
  

 

	1 	 Include appropriate other stockholders so that, together with FMR, they hold sufficient voting power for the election of a director.

	2 	 Such resignation to be effective immediately prior to filing of S-1. 

  
 1 

 
Mucci, shall be reasonably acceptable to the Board of Directors is elected to the Board, including, if necessary, to amend the By-Laws of the Company to create an additional vacancy on the Board
and to fill such vacancy with one person designated by FVL. 
 1.2. Observer Rights. Following the effective date of this
Voting Agreement, the Company shall invite a representative of FVL designated by FVL who, if other than Mr. Mucci, shall be reasonably acceptable to the Board of Directors to attend all meetings of its Board and any committees thereof of which
Mr. Mucci was a member at the time of execution of this Agreement in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors; provided, however, that as a condition precedent to the foregoing such representative shall execute a non-disclosure agreement in form and substance reasonably
acceptable to the Company; and provided further, that the observation rights described herein shall be qualified, and the FVL representative shall recuse himself from any meeting of the Board of Directors, to the extent necessary, in the opinion of
counsel to the Company, to avoid any waiver of the attorney-client privilege with respect to any matter that could be materially injurious to the interests of the Company. Such observation rights shall terminate and be of no further force or effect
upon termination of this Voting Agreement pursuant to Section 3 below. 
 1.3. Consent. All Stockholders
agree to execute any written consents required to perform the obligations of this Agreement. 
 2. Remedies. 

2.1. Covenants of the Company. The Company agrees to use its best efforts, within the requirements of applicable law, to ensure
that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement. Such actions include, without limitation, the use of the Company’s best efforts to cause the nomination and election of the
director as provided in this Agreement. 
 2.2. Irrevocable Proxy and Power of Attorney. Each Stockholder hereby
constitutes and appoints as the proxy of the party and hereby grants a power of attorney to Paul Mucci, with full power of substitution, solely with respect to the matters set forth in Section 1.1 to authorize such person to vote in the manner
specified in Section 1.1 on such matters. In addition, each Stockholder hereby authorizes such proxy to represent and to vote, if and only if the Stockholder (i) fails to vote or (ii) attempts to vote (whether by proxy, in person or
by written consent), in a manner which is inconsistent with the terms of this Agreement, all of such party’s Shares in the manner specified in Section 1.1. Such proxy and powers of attorney granted pursuant to the immediately preceding
sentence is given in consideration of the agreements and covenants of the Company and the Stockholders in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless
and until this Agreement terminates or expires pursuant to Section 3 hereof. Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the voting of the Shares and shall not hereafter, unless and
until this Agreement terminates or expires pursuant to Section 3 hereof, purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement
(other than this Agreement), arrangement or understanding with any person, directly 

 
or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Shares, in each case, solely with respect to any of the matters set forth herein. 

2.3. Specific Enforcement. Each party acknowledges and agrees that each of the Fidelity entities will be irreparably damaged in
the event any of the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that each of the Fidelity Entities shall be entitled to an injunction to
prevent breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United States or any state having subject matter jurisdiction. 

2.4. Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be
cumulative and not alternative. 
 3. Term. This Agreement shall be effective as of the date hereof and shall continue in
effect until and shall terminate upon the earliest to occur of (a) the consummation of the Company’s IPO, (b) the consummation of a deemed liquidation event of the Company in accordance with the final sentence of Article Fourth.(I).4A
of the Company’s Certificate of Incorporation, and (c) appointment of the FVL Designee as a director of the Company by action of the Board of Directors, or (d) a special meeting (or action by written consent) of the stockholders of
the Company pursuant to which the representative of FVL is appointed to the Board pursuant to Section 1.1. 
 4.
Miscellaneous. 
 4.1. Successors and Assigns. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 4.2. Governing Law. This Agreement shall be governed by the internal law of the State of Delaware. 
 4.3. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 4.4. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 4.5. Notices. All notices and other communications
given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by

 
electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, provided a copy is also sent via email, or (d) one (1) business day after the business day of deposit with a nationally
recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt, provided a copy is also sent via email. All communications shall be sent to the respective parties at their address as set
forth on the signature page or Schedule A hereto with copies to counsel as therein indicated, or to such email address, facsimile number or address as subsequently modified by written notice given in accordance with this Subsection
4.5. 
 4.6. Consent Required to Amend, Terminate or Waive. This Agreement may not be amended or terminated and the
observance of any term hereof may not be waived (either generally or in a particular instance and either retroactively or prospectively) without the prior written consent of FVL. 

4.7. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or
approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the
extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 4.8. Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 

4.9. Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with respect
to the subject matter hereof, and any other previous written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 
 4.10. Manner of Voting. The voting of Shares pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other manner permitted by applicable law. For the avoidance
of doubt, voting of the Shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement. 

4.11. Further Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other,
and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions
contemplated hereby and to otherwise carry out the intent of the parties hereunder. 

 4.12. Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of the Commonwealth of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of
or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the Commonwealth of Massachusetts or the United States District Court for the
District of Massachusetts, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject
matter hereof may not be enforced in or by such court. 
 4.13. WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS
RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT
MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO
AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL
RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

 IN WITNESS WHEREOF, the parties have executed this Voting Agreement as of the date first
written above. 
  

			
	EXA CORPORATION
		
	By:	 	/s/ Stephen Remondi
	 Name:
 Title:
	 	

  
  

			
	 FIDELITY VENTURES LIMITED
  

Fidelity Capital Associates, Inc., its general partner

		
	Signature:	 	/s/ Paul L. Mucci
	Name:	 	Paul L. Mucci

  
  

			
	 INFOTECH FUND I LLC
  

By: Star Horizon Management LLC, its manager

		
	Signature:	 	/s/ Paul L. Mucci
	Name:	 	Paul L. Mucci

  
  

			
	FMR LLC
		
	Signature:	 	/s/ Steven F. Schiffin
	Name:	 	Steven F. Schiffin

  
  

	
	 Address:
  
 with a copy for notices to:
 McDermott Will & Emery LLP

340 Madison Ave.
 New York, NY 10173

Attn: David Goldman, Esq.
 Fax:
(212) 547-5444

  
  

			
	BOSTON CAPITAL VENTURES III, LIMITED PARTNERSHIP
		
	By:	 	/s/ Johan van der Goltz

  
  

			
	BOSTON CAPITAL VENTURES IV, LIMITED PARTNERSHIP
		
	By:	 	/s/ John J. Shields, IIIAmendment & Waiver by and among Exa Corporation and the stockholders of Exa Corp

 Exhibit 4.12 
 AMENDMENT AND WAIVER 
 THIS AMENDMENT AND WAIVER (this “Amendment and
Waiver”) is entered into as of February 15, 2008 by and among Exa Corporation, Delaware corporation (the “Company”), and the undersigned stockholders of the Company (the “Requisite Shareholders”). 

WHEREAS, pursuant to the terms of the Purchase Agreements (as defined in Section 6) (i) certain stockholders of the Company
have registration rights with respect to certain shares of the Company’s capital stock (“Registration Rights”), and (ii) the Company is required, prior to the issuance by the Company of any of its securities (other than debt
securities with no equity feature), to offer to certain stockholders of the Company the right to purchase their Proportionate Percentage (as defined below) of such securities (the “Participation Rights”); 

WHEREAS, the Company proposes to enter into a certain Stock Purchase Agreement (the “Series I SPA”; capitalized terms used but
not defined herein shall have the meanings ascribed to such terms in the Series I SPA) dated as of the date hereof by and among (i) the Company, (ii) Boston Capital Ventures III, Limited Partnership (“BCV III”) and Boston Capital
Ventures IV, Limited Partnership (“BCV IV” and, together with BCV III, “BCV”), and (iii) FMR Corporation (“FMR”) and Fidelity Ventures Ltd. (“Fidelity Ventures” and, together with FMR,
“Fidelity”) (collectively, the “Investors”); 
 WHEREAS, pursuant to the Series I SPA, the Company proposes
to (i) issue and sell to the Investors up to an aggregate of 3,378,381 shares of the Company’s Series I Convertible Preferred Stock, $0.001 par value per share (the “Series I Preferred Stock”) at a purchase price of $1.48 per
share (the “Cash Financing”), (ii) issue and sell to BCV up to an aggregate of (a) 677,043 shares of the Company’s Series I Preferred Stock and (b) 1,002,024 shares of the Company’s Common Stock, $0.001 par value
per share (“Common Stock”), in exchange for the cancellation of indebtedness represented by the Company’s non-convertible promissory notes (the “Non-Convertible Notes”) issued to BCV III and BCV IV on February 9, 2004
in the original principal amount of $184,078.10 and $1,168,072.30, respectively (the “Debt Conversion”), and (iii) grant registration rights to the Investors with respect to the Series I Preferred Stock purchased pursuant to the
Series I SPA; 
 WHEREAS, the written consent of the Company and the holders of at least (i) 51% of the outstanding shares
of the Company’s Series A Preferred Stock, (ii) 80% of the outstanding shares of Series B Preferred Stock, (iii) 80% of the outstanding shares of Series C Preferred Stock, (iv) 80% of the outstanding shares of Series E Preferred
Stock, (v) 80% of the outstanding shares of Series F Preferred Stock, and (vi) 70% of the aggregate amount of the shares of Series H Preferred Stock that would be issued upon conversion of the Series H Notes (as defined in the Series H
Purchase Agreement) as if converted on the date of such consent, is necessary to waive the Participation Rights (and notice of such rights) on behalf of all stockholders entitled to such rights; 

 WHEREAS, the written consent of the Company and the holders of at least (i) a majority
of the shares of Series A Preferred Stock, (ii) a majority of the shares of Series B Preferred Stock, and (iii) 67% of the Registrable Securities (as defined in the Purchase Agreements), including at least two Institutional Holders (as
defined in the Purchase Agreements) is necessary to amend Section 8 of the Purchase Agreements; and 
 WHEREAS, the
Requisite Shareholders hold a sufficient number of shares of each series of Preferred Stock necessary to (i) waive the Participation Rights on behalf of all stockholders with respect to both the Cash Financing and the Debt Conversion, and
(ii) amend the Purchase Agreements and the terms of the Registration Rights provided for therein. 
 NOW, THEREFORE, the
Company and the undersigned Requisite Shareholders hereby agree as follows: 
 1. Amendment of Registration Rights Under the
Purchase Agreements. 
 1.1 The Series A Purchase Agreement. Effective as of the Closing,
Section 8 of the Series A Purchase Agreement is hereby amended by the deletion thereof in its entirety and the insertion in the place thereof the text of Section 8 in its entirety of the Series I SPA. The defined terms contained in such
Section 8 of the Series I SPA shall be used in Section 8 of the Series A Purchase Agreement, as amended hereby, as so defined in the Series I SPA. Section 8 of the Series A Purchase Agreement, as amended hereby, and any defined terms
used therein, shall only be amended by written approval by the Company and a majority of the holders of the Company’s Series A Preferred Stock provided, any such amendment shall also be approved as provided in Section 9.5 of the Series I
SPA. 
 1.2 The Series B Purchase Agreement. Effective as of the Closing, Section 8 of the Series B
Purchase Agreement is hereby amended by the deletion thereof in its entirety and the insertion in the place thereof the text of Section 8 in its entirety of the Series I SPA. The defined terms contained in such Section 8 of the Series I
SPA shall be used in Section 8 of the Series B Purchase Agreement, as amended hereby, as so defined in the Series I SPA. Section 8 of the Series B Purchase Agreement, as amended hereby, and any defined terms used therein, shall only be
amended by written approval by the Company and a majority of the holders of the Company’s Series B Preferred Stock provided, any such amendment shall also be approved as provided in Section 9.5 of the Series I SPA. 

1.3 The Series C Purchase Agreement, the Series E Purchase Agreement, the Series F Purchase Agreement and the Series H
Purchase Agreement. Effective as of the Closing, Section 8 of each of the Series C Purchase Agreement, the Series E Purchase Agreement, the Series F Purchase Agreement, and the Series H Purchase Agreement (the “Series C, E, F and H
Purchase Agreements”) is hereby amended by the deletion thereof in its entirety and the insertion in the place thereof the text of Section 8 in it entirety of the Series I SPA. The defined terms contained in such Section 8 of the
Series I SPA shall be used in Section 8 of each of the Series C, E, F, and H Purchase Agreements, as amended hereby, as so defined in the Series I SPA. Section 8 of each of the Series C, E, F, and H Purchase Agreements, as amended hereby,
and any defined terms used therein, shall only be approved as provided in Section 9.5 of the Series I SPA. 

  
 - 2 -

 2. Amendment of Redemption Rights. By signing this Amendment and Waiver, W Capital
Partners Mustang, L.P. hereby consents to the deletion of Section 7 of the Company’s Certificate of Incorporation, as amended, in its entirety (including, without limitation, the redemption rights provided for therein). 

3. Waiver of Participation Rights. By signing this Amendment and Waiver, the Company and the Requisite Shareholders hereby waive
the Participation Rights to participate in the Cash Financing and the Debt Conversion, and waive notice of such Participation Rights, on behalf of all stockholders entitled to such rights. 

4. Acknowledgment of Interested Directors. Each of the Requisite Shareholders acknowledges that they (a) understand the
interests of each of the Company’s Board of Directors in the consummation of the Cash Financing and the Debt Conversion and (b) consider the terms of the Cash Financing and the Debt Conversion to be fair to the Company’s security
holders. 
 5. Acknowledgment of Information. Each of the Requisite Shareholders acknowledges that they have had the
opportunity to read, understand, review and consider all of the provisions of this Amendment and Waiver and the Series I SPA and that they have had the opportunity to discuss such documents with legal counsel of their own choosing and that they have
had the opportunity to ask questions of the Company. 
 6. Miscellaneous. Except to the extent specifically modified
hereby, the provisions of the Purchase Agreements shall remain unmodified, and the Purchase Agreements as amended hereby are confirmed as being in full force and effect. This agreement may be executed in any number of counterparts which together
shall constitute a single instrument and shall be governed by and construed in accordance with the domestic substantive laws of The Commonwealth of Massachusetts. 
 7. Definitions. Reference is made to (i) the Series A Preferred Stock and Warrant Purchase Agreement dated April 30, 1993, as amended on November 2, 1994, September 30,
1996, November 27, 1996 and January 28, 1998, among the Company and the Investors party thereto (as amended, the “Series A Purchase Agreement”), (ii) the Series B Convertible Preferred Stock Purchase Agreement dated
November 2, 1994, as amended on September 30, 1996, November 27, 1996 and January 28, 1998, among the Company and the Investors party thereto (the “Series B Purchase Agreement”), (iii) the Series C Convertible
Preferred Stock Purchase Agreement dated September 30, 1996, as amended on November 27, 1996 and January 28, 1998, among the Company and the Investors party thereto (the “Series C Purchase Agreement”), (iv) the Series E
Convertible Stock Purchase Agreement dated January 28, 1998 among the Company and the Investors party thereto (the “Series E Purchase Agreement”), (v) the Series F Convertible Stock Purchase Agreement dated January 28, 1998
among the Company and the Investor party thereto (the “Series F Purchase Agreement”), and (vi) the Note Purchase Agreement dated February 9, 2004 among the Company and the Investors party thereto (the “Series H Purchase
Agreement”) (collectively, the “Purchase Agreements”). The Series C Purchase Agreement, the Series E Purchase Agreement, the Series F Purchase Agreement, and the Series H Purchase Agreement are collectively referred to herein as the
“Series C, E, F, and H Purchase Agreements.” Terms defined in the Purchase Agreements, as amended hereby, and not otherwise defined herein are used herein as so defined. 

  
 - 3 -

 8. Effectiveness. This Amendment and Wavier shall become a binding agreement when the
Company has received copies of this Amendment and Waiver executed by the Company and the holders of at least (i) 51% of the outstanding shares of Series A Preferred Stock, (ii) 80% of the outstanding shares of Series B Preferred Stock
(iii) 80% of the outstanding shares of Series C Preferred Stock, (iv) 80% of the outstanding shares of Series E Preferred Stock, (v) 80% of the outstanding shares of Series F Preferred Stock, and (vi) 70% of the aggregate amount
of the shares of Series H Preferred Stock that would be issued upon conversion of the Series H Notes. 
 *   *
  * 

  
 - 4 -

 IN WITNESS WHEREOF, the undersigned parties have executed this Amendment and Waiver as an
instrument under seal. 
  

			
	EXA CORPORATION
		
	By:	 	/s/ Stephen A. Remondi
	Title:	 	President and CEO
	
	 
	Kim Molvig
	
	/s/ James Popeo
	James Popeo
	
	/s/ Stephen A. Remondi
	Stephen A. Remondi
	
	/s/ John J. Shields, III
	John J. Shields, III

 FIDELITY VENTURES LTD. 
 Fidelity Capital Associates, Inc., Its Managing General Partner 
  

			
	By:	 	/s/ [ILLEGIBLE]
	Title:	 	Assistant Treasurer

 FIDELITY INVESTORS LIMITED PARTNERSHIP 
 By:   Northern Neck Investors Corporation, Its General Partner 
  

			
	By:	 	/s/ [ILLEGIBLE]
	Title:	 	Chief Financial Officer

  
 - 5 -

 FMR LLC 
  

			
	By:	 	/s/ [ILLEGIBLE]
	Title:	 	Assistant Treasurer

 BOSTON CAPITAL VENTURES III, LIMITED PARTNERSHIP 

 

			
	By:	 	/s/ [ILLEGIBLE]
	Title:	 	General Partner

 BOSTON CAPITAL VENTURES IV, LIMITED PARTNERSHIP 

 

			
	By:	 	/s/ John J. Shields, III
	Title:	 	General Partner

 MASSACHUSETTS CAPITAL RESOURCE COMPANY 
  

			
	By:	 	/s/ Kenneth J. Lavery
	Title:	 	Vice President

 W CAPITAL PARTNERS MUSTANG, L.P. 
  

			
	By:	 	WCP I, L.L.C., Its General Partner
	By:	 	/s/ Robert Miglione
	Title:	 	Managing Member

  
 - 6 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]